233 related articles for article (PubMed ID: 27512672)
1. Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy.
Sampath P; Thorne SH
Oncolytic Virother; 2015; 4():75-82. PubMed ID: 27512672
[TBL] [Abstract][Full Text] [Related]
2. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
3. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
[TBL] [Abstract][Full Text] [Related]
4. Poxvirus oncolytic virotherapy.
Torres-DomĂnguez LE; McFadden G
Expert Opin Biol Ther; 2019 Jun; 19(6):561-573. PubMed ID: 30919708
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials.
LaRocca CJ; Warner SG
Clin Transl Med; 2018 Nov; 7(1):35. PubMed ID: 30426287
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses.
Hoare J; Campbell N; Carapuça E
Porto Biomed J; 2018 Aug; 3(1):e7. PubMed ID: 31595233
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
Cervera-Carrascon V; Havunen R; Hemminki A
Expert Opin Biol Ther; 2019 May; 19(5):443-455. PubMed ID: 30905206
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment.
Rosewell Shaw A; Suzuki M
Front Immunol; 2018; 9():2103. PubMed ID: 30298067
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic virus immunotherapy: future prospects for oncology.
Raja J; Ludwig JM; Gettinger SN; Schalper KA; Kim HS
J Immunother Cancer; 2018 Dec; 6(1):140. PubMed ID: 30514385
[TBL] [Abstract][Full Text] [Related]
11. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
12. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Rajani KR; Vile RG
Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
[TBL] [Abstract][Full Text] [Related]
13. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
14. Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.
Bastin D; Walsh SR; Al Saigh M; Wan Y
Biomedicines; 2016 Aug; 4(3):. PubMed ID: 28536388
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic viruses as engineering platforms for combination immunotherapy.
Twumasi-Boateng K; Pettigrew JL; Kwok YYE; Bell JC; Nelson BH
Nat Rev Cancer; 2018 Jul; 18(7):419-432. PubMed ID: 29695749
[TBL] [Abstract][Full Text] [Related]
16. The viral approach to breast cancer immunotherapy.
Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
[TBL] [Abstract][Full Text] [Related]
17. The Role of Oncolytic Viruses in the Treatment of Melanoma.
Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
[TBL] [Abstract][Full Text] [Related]
18. Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?
Koks CA; De Vleeschouwer S; Graf N; Van Gool SW
J Cancer; 2015; 6(3):203-17. PubMed ID: 25663937
[TBL] [Abstract][Full Text] [Related]
19. Immune and viral therapies for malignant primary brain tumors.
Gardeck AM; Sheehan J; Low WC
Expert Opin Biol Ther; 2017 Apr; 17(4):457-474. PubMed ID: 28274139
[TBL] [Abstract][Full Text] [Related]
20. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]